$RIGL
RIGEL PHARMACEUTICALS INC

2023 Q3 Form 10-Q Financial Statement

#000155837023012722 Filed on August 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $28.13M $26.89M
YoY Change 25.54% -9.84%
Cost Of Revenue $1.268M $1.075M
YoY Change 407.2% 3.76%
Gross Profit $26.87M $25.81M
YoY Change 21.24% -10.33%
Gross Profit Margin 95.49% 96.0%
Selling, General & Admin $24.86M $26.31M
YoY Change -4.02% -2.5%
% of Gross Profit 92.52% 101.92%
Research & Development $6.475M $4.772M
YoY Change -55.85% -67.68%
% of Gross Profit 24.1% 18.49%
Depreciation & Amortization $300.0K $296.0K
YoY Change 25.0% 24.89%
% of Gross Profit 1.12% 1.15%
Operating Expenses $31.33M $31.08M
YoY Change -22.76% -25.56%
Operating Profit -$4.465M -$5.267M
YoY Change -75.74% -59.38%
Interest Expense $1.899M -$1.333M
YoY Change 129.9% -334.27%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.690M -$6.600M
YoY Change -70.11% -51.08%
Income Tax
% Of Pretax Income
Net Earnings -$5.692M -$6.600M
YoY Change -70.1% -51.08%
Net Earnings / Revenue -20.23% -24.55%
Basic Earnings Per Share -$0.03 -$0.04
Diluted Earnings Per Share -$0.03 -$0.04
COMMON SHARES
Basic Shares Outstanding 174.4M 173.7M
Diluted Shares Outstanding 174.4M 173.7M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.40M $64.36M
YoY Change -23.57% -27.82%
Cash & Equivalents $45.41M $48.81M
Short-Term Investments $16.90M $15.55M
Other Short-Term Assets $3.000M $4.967M
YoY Change -51.27% -37.44%
Inventory $6.112M $10.78M
Prepaid Expenses
Receivables $23.55M $20.82M
Other Receivables $0.00 $0.00
Total Short-Term Assets $95.02M $100.9M
YoY Change -13.96% -16.26%
LONG-TERM ASSETS
Property, Plant & Equipment $190.0K $1.212M
YoY Change -88.78% -33.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.956M $541.0K
YoY Change 923.97% 34.24%
Total Long-Term Assets $20.30M $16.17M
YoY Change 292.73% 116.12%
TOTAL ASSETS
Total Short-Term Assets $95.02M $100.9M
Total Long-Term Assets $20.30M $16.17M
Total Assets $115.3M $117.1M
YoY Change -0.25% -8.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.999M $5.240M
YoY Change 193.97% 143.16%
Accrued Expenses $19.60M $18.04M
YoY Change -47.4% -54.24%
Deferred Revenue $1.355M $1.355M
YoY Change -1.02% -12.18%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $48.27M $44.02M
YoY Change 2.13% -19.89%
LONG-TERM LIABILITIES
Long-Term Debt $59.70M $59.57M
YoY Change 51.26% 99.68%
Other Long-Term Liabilities $38.76M $41.61M
YoY Change -20.43% -11.26%
Total Long-Term Liabilities $38.76M $101.2M
YoY Change -20.43% 115.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.27M $44.02M
Total Long-Term Liabilities $38.76M $101.2M
Total Liabilities $147.2M $145.2M
YoY Change 53.33% 42.58%
SHAREHOLDERS EQUITY
Retained Earnings -$1.408B -$1.403B
YoY Change 1.77% 2.77%
Common Stock $1.376B $1.375B
YoY Change 0.89% 0.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$31.83M -$28.12M
YoY Change
Total Liabilities & Shareholders Equity $115.3M $117.1M
YoY Change -0.25% -8.52%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$5.692M -$6.600M
YoY Change -70.1% -51.08%
Depreciation, Depletion And Amortization $300.0K $296.0K
YoY Change 25.0% 24.89%
Cash From Operating Activities -$1.360M $5.930M
YoY Change -89.78% -145.93%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$1.170M $2.970M
YoY Change -110.99% -85.9%
Cash From Investing Activities -$1.170M $2.970M
YoY Change -111.19% -85.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -870.0K -373.0K
YoY Change -115.79% -93.41%
NET CHANGE
Cash From Operating Activities -1.360M 5.930M
Cash From Investing Activities -1.170M 2.970M
Cash From Financing Activities -870.0K -373.0K
Net Change In Cash -3.400M 8.527M
YoY Change -227.58% 238.1%
FREE CASH FLOW
Cash From Operating Activities -$1.360M $5.930M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.360M $5.930M
YoY Change -89.63% -145.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
173748000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172147000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
173659000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
171961000
CY2023Q2 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2022Q2 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
dei Entity Registrant Name
EntityRegistrantName
RIGEL PHARMACEUTICALS INC
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001034842
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 rigl Collaborative Arrangement Revenue Recognized
CollaborativeArrangementRevenueRecognized
20000000
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-29889
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3248524
dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Boulevard, Suite 900,
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
624-1100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RIGL
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
174364286
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48812000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24459000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
15545000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
33747000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20819000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40320000
CY2023Q2 us-gaap Inventory Net
InventoryNet
10782000
CY2022Q4 us-gaap Inventory Net
InventoryNet
9118000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4967000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8259000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
100925000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
115903000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
215000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
857000
CY2023Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
14413000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
14949000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
997000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1930000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
541000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
640000
CY2023Q2 us-gaap Assets
Assets
117091000
CY2022Q4 us-gaap Assets
Assets
134279000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5240000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22508000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6739000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8866000
CY2023Q2 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
5826000
CY2022Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
7708000
CY2023Q2 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
13684000
CY2022Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
12145000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5013000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6485000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
466000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1133000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1355000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1369000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5700000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4997000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44023000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65211000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
628000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
972000
CY2023Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
59574000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
39448000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
40981000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42264000
CY2023Q2 us-gaap Liabilities
Liabilities
145206000
CY2022Q4 us-gaap Liabilities
Liabilities
147895000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
175000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
174000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1374330000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1368822000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-25000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-153000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1402595000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1382459000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-28115000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-13616000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117091000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134279000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26886000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29819000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52956000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46554000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1075000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1036000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2052000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1157000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4772000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14767000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14861000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30241000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26306000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26981000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54035000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54382000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
32153000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
42784000
us-gaap Costs And Expenses
CostsAndExpenses
70948000
us-gaap Costs And Expenses
CostsAndExpenses
85780000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5267000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12965000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17992000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39226000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
529000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
us-gaap Investment Income Interest
InvestmentIncomeInterest
922000
us-gaap Investment Income Interest
InvestmentIncomeInterest
63000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1862000
CY2022Q2 us-gaap Interest Expense
InterestExpense
569000
us-gaap Interest Expense
InterestExpense
3066000
us-gaap Interest Expense
InterestExpense
1774000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6600000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13492000
us-gaap Net Income Loss
NetIncomeLoss
-20136000
us-gaap Net Income Loss
NetIncomeLoss
-40937000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
173748000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172147000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
173659000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171961000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6600000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13492000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20136000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40937000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-22000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
128000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-336000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6598000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13514000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20008000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41273000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-13616000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13536000
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
126000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2768000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-24257000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6600000
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
554000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2186000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-28115000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30374000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27445000
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-314000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
940000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3243000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
6798000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13492000
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-22000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
599000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2440000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3677000
us-gaap Profit Loss
ProfitLoss
-20136000
us-gaap Profit Loss
ProfitLoss
-40937000
us-gaap Share Based Compensation
ShareBasedCompensation
4930000
us-gaap Share Based Compensation
ShareBasedCompensation
5598000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-398000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
253000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
653000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
474000
rigl Noncash Interest Expense
NoncashInterestExpense
682000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
114000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-107000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-19501000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1726000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1640000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-483000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3292000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
527000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-99000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-571000
rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
933000
rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
4458000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2268000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1585000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2127000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3165000
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-1882000
rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-1171000
rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
1539000
rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
2316000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1472000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1878000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1011000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4840000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1053000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1175000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
142000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1856000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38548000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
8780000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6997000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
27400000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
50645000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
15000000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
127000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
264000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
188000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3747000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43724000
rigl Payment Of Cost Share To Collaboration Partner
PaymentOfCostShareToCollaborationPartner
1754000
rigl Payment Of Cost Share To Collaboration Partner
PaymentOfCostShareToCollaborationPartner
8346000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
554000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1539000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19950000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
9942000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3135000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
24353000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8311000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24459000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18890000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48812000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27201000
us-gaap Interest Paid Net
InterestPaidNet
2485000
us-gaap Interest Paid Net
InterestPaidNet
951000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:9pt;text-indent:36pt;margin:9pt 0pt 0pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from these estimates.</p>
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
64400000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37207000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34272000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37207000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34272000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26886000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29819000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52956000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46554000
rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
18600000
rigl Sales Discounts And Allowances
SalesDiscountsAndAllowances
13000000.0
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
12145000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
18559000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
17020000
CY2023Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
13684000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
7915000
us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
13004000
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
10688000
CY2022Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
10231000
rigl Contingent Payments Under Agreement
ContingentPaymentsUnderAgreement
1300000000
CY2021Q2 rigl Collaborative Arrangement Upfront Fee Received
CollaborativeArrangementUpfrontFeeReceived
125000000.0
rigl Right To Opt Out Of Agreement Number Of Periods
RightToOptOutOfAgreementNumberOfPeriods
2
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2172000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2391000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4930000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5598000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
800000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
108600
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
4000000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
12186098
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
6878000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4555000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
2046000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2659000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1858000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1904000
CY2023Q2 us-gaap Inventory Net
InventoryNet
10782000
CY2022Q4 us-gaap Inventory Net
InventoryNet
9118000
CY2023Q2 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
700000
CY2022Q4 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
800000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
64357000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
58206000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48812000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24459000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
15545000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
33747000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
64357000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
58206000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34479000
CY2023Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
34454000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
47940000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
47787000
rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P72D
CY2022 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P89D
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
19
CY2023Q2 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2022Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
18526000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
29000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
600000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
7500000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
30000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
22500000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
60000000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
166000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1340000
us-gaap Operating Lease Cost
OperatingLeaseCost
778000
us-gaap Operating Lease Cost
OperatingLeaseCost
2680000
CY2023Q2 rigl Variable Lease Expense Net Credit
VariableLeaseExpenseNetCredit
-42000
CY2022Q2 rigl Variable Lease Expense Net Credit
VariableLeaseExpenseNetCredit
125000
rigl Variable Lease Expense Net Credit
VariableLeaseExpenseNetCredit
30000
rigl Variable Lease Expense Net Credit
VariableLeaseExpenseNetCredit
391000
CY2023Q2 us-gaap Lease Cost
LeaseCost
124000
CY2022Q2 us-gaap Lease Cost
LeaseCost
1465000
us-gaap Lease Cost
LeaseCost
808000
us-gaap Lease Cost
LeaseCost
3071000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
178000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
2630000
us-gaap Operating Lease Payments
OperatingLeasePayments
1174000
us-gaap Operating Lease Payments
OperatingLeasePayments
5226000
CY2022Q2 rigl Fixed Sublease Expense
FixedSubleaseExpense
1095000
rigl Fixed Sublease Expense
FixedSubleaseExpense
365000
rigl Fixed Sublease Expense
FixedSubleaseExpense
2190000
CY2022Q2 rigl Variable Sublease Expense
VariableSubleaseExpense
206000
rigl Variable Sublease Expense
VariableSubleaseExpense
77000
rigl Variable Sublease Expense
VariableSubleaseExpense
450000
CY2022Q2 us-gaap Sublease Income
SubleaseIncome
1301000
us-gaap Sublease Income
SubleaseIncome
442000
us-gaap Sublease Income
SubleaseIncome
2640000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
360000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
739000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
301000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1400000

Files In Submission

Name View Source Status
0001558370-23-012722-index-headers.html Edgar Link pending
0001558370-23-012722-index.html Edgar Link pending
0001558370-23-012722.txt Edgar Link pending
0001558370-23-012722-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rigl-20230630.xsd Edgar Link pending
rigl-20230630x10q.htm Edgar Link pending
rigl-20230630x10q004.jpg Edgar Link pending
rigl-20230630xex10d1.htm Edgar Link pending
rigl-20230630xex10d2.htm Edgar Link pending
rigl-20230630xex10d3.htm Edgar Link pending
rigl-20230630xex31d1.htm Edgar Link pending
rigl-20230630xex31d2.htm Edgar Link pending
rigl-20230630xex32d1.htm Edgar Link pending
Show.js Edgar Link pending
rigl-20230630_def.xml Edgar Link unprocessable
rigl-20230630_pre.xml Edgar Link unprocessable
rigl-20230630x10q_htm.xml Edgar Link completed
rigl-20230630_cal.xml Edgar Link unprocessable
rigl-20230630_lab.xml Edgar Link unprocessable